UNICYCIVE THERAPEUTICS, INC. Adjustment of Warrants Granted for Services
UNICYCIVE THERAPEUTICS, INC. (UNCY) reported Adjustment of Warrants Granted for Services of $13.70 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:AdjustmentOfWarrantsGrantedForServices · last filed 2026-08-12
- UNICYCIVE THERAPEUTICS, INC. adjustment of warrants granted for services for the quarter ending 2026-06-30 was -$8.00M.
- UNICYCIVE THERAPEUTICS, INC. adjustment of warrants granted for services for the quarter ending 2026-03-31 was $21.70M, a 104.72% increase year-over-year.
- UNICYCIVE THERAPEUTICS, INC. adjustment of warrants granted for services for the quarter ending 2025-12-31 was $7.80M, a 37.60% decline year-over-year.
- UNICYCIVE THERAPEUTICS, INC. adjustment of warrants granted for services for the quarter ending 2025-09-30 was -$1.10M.
- UNICYCIVE THERAPEUTICS, INC. adjustment of warrants granted for services for fiscal 2024 was $18.90M, a 44.27% increase from fiscal 2023.
- UNICYCIVE THERAPEUTICS, INC. adjustment of warrants granted for services for fiscal 2023 was $13.10M.
| Period end | Adjustment of Warrants Granted for Services 0 month | Adjustment of Warrants Granted for Services | Adjustment of Warrants Granted for Services 3 month | Adjustment of Warrants Granted for Services 6 month | Adjustment of Warrants Granted for Services 9 month | Adjustment of Warrants Granted for Services 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | -$8.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $13.70M 10-Q · filed 2026-08-12 | $21.50M derived: sum of 3 quarters · filed 2026-08-12 | $20.40M derived: sum of 4 quarters · filed 2026-08-12 | ||
| 2026-03-31 | $21.70M 10-Q · filed 2026-05-12 | $29.50M derived: sum of 2 quarters · filed 2026-08-12 | $28.40M derived: sum of 3 quarters · filed 2026-08-12 | $28.00M derived: sum of 4 quarters · filed 2026-08-12 | ||
| 2025-12-31 | $7.80M derived: 10-Q 12 month − 10-Q 9 month · filed 2026-08-12 | $6.70M derived: sum of 2 quarters · filed 2026-08-12 | $6.30M derived: sum of 3 quarters · filed 2026-08-12 | $16.90M 10-Q · filed 2026-08-12 | ||
| 2025-09-30 | -$1.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$1.50M derived: sum of 2 quarters · filed 2025-11-12 | $9.10M 10-Q · filed 2025-11-12 | $21.60M derived: sum of 4 quarters · filed 2026-03-30 | ||
| 2025-06-30 | -$400.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $10.20M 10-Q · filed 2025-08-14 | $22.70M derived: sum of 3 quarters · filed 2026-03-30 | $21.00M derived: sum of 4 quarters · filed 2026-03-30 | ||
| 2025-03-31 | $10.60M 10-Q · filed 2025-05-14 | $23.10M derived: sum of 2 quarters · filed 2026-03-30 | $21.40M derived: sum of 3 quarters · filed 2026-03-30 | $4.60M derived: sum of 4 quarters · filed 2026-03-30 | ||
| 2024-12-31 | $12.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $10.80M derived: sum of 2 quarters · filed 2026-03-30 | -$6.00M derived: sum of 3 quarters · filed 2026-03-30 | $18.90M 10-K · filed 2026-03-30 | ||
| 2024-09-30 | -$1.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$18.50M derived: sum of 2 quarters · filed 2024-11-13 | $6.40M 10-Q · filed 2024-11-13 | $8.00M derived: sum of 4 quarters · filed 2025-03-31 | ||
| 2024-06-30 | -$16.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $8.10M 10-Q · filed 2024-08-14 | $9.70M derived: sum of 3 quarters · filed 2025-03-31 | |||
| 2024-03-31 | $24.90M 10-Q · filed 2024-05-13 | $26.50M derived: sum of 2 quarters · filed 2025-03-31 | ||||
| 2023-12-31 | $1.60M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $13.10M 10-K · filed 2025-03-31 | ||||
| 2023-09-30 | $11.50M 10-Q · filed 2023-11-14 | |||||
| 2023-03-03 | $2.80M 10-Q · filed 2023-11-14 | $2.80M 10-Q · filed 2026-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |